Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.
Financial Highlights -- Second quarter sales increased 131% to $10.3 million on a sequential quarter basis and decreased by 49% year-over-year -- Sales for the six-month period declined 45% to $14.7 million, compared to same period last year -- Net income attributable to shareholders for the second quarter was $1.0 million, with net income per diluted share of $0.02 -- Net income attributable to shareholders for the six-month period was $738,000, with net income per diluted share of $0.01 -- Cash and cash equivalents at June 30, 2010 was $94.6 million Business Highlights -- In May 2010, Sinovac was selected by the Beijing Centers for Diseases Control and Prevention (Beijing CDC) to supply the Company's
hepatitis A vaccine, Healive, to the Beijing Expanded Program of Immunization (EPI). Based on the comprehensive score following the Beijing CDC's evaluation of potential suppliers, Sinovac was selected as one of the two suppliers and was allocated a greater share of the total purchase order. The total ordered quantity allocated to Sinovac was approximately 477,000 doses. -- In June 2010, Sinovac participated at the 2010 Shanghai CPHI Exhibition. At the exhibition, Sinovac showcased its commercialized products, including its Healive, Anflu, Panflu and Panflu.1
vaccines. The Company met with several prospective distribution partners aimed at commercializing Sinovac's vaccines in targeted international markets. -- In August 2010, Sinovac received the GMP Inspection Report from the Government of Nepal's Ministry of Health and Population. The report stated that Sinovac's production facilities are qualified for registering its hepatitis A vaccine, Healive, for importation to Nepal. The favorable inspection report represents a key step towards obtaining the product registration certificate from the Nepalese Government. It is anticipated that Sinovac will be granted the product registration certificate later this year.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "The Shanxi vaccine incident continues to impact the public's confidence in vaccine safety as it has significantly affected demand across the private pay market. Although we cannot alter the market environment, we are effectively adjusting our marketing and sales strategies to address the market situation and to enhance our capabilities. We increased the size of our sales force to further expand domestic market penetration and to improve the effectiveness of our promotion strategies. We are beginning to see results as evidenced by the 131% increase in sales in second quarter as compared to the first quarter. We will continue to refine and implement our marketing and sales strategies to improve our competencies and increase our market share."
Mr. Yin continued, "The 2010 seasonal flu season commenced in the third quarter. Our first batch of Anflu has been released by the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) and launched into the market. Our sales team has already started the promotion activities in several areas. Although a level of uncertainty surrounds the seasonal flu vaccine market, we remain confident about our ability to advance the development of flu vaccine market in China."
Mr. Yin continued, "Our capacity expansion project for flu vaccine is progressing well. Currently the flu production facilities are under design in compliance with WHO GMP standards and the equipments are being selected, which means we are moving forward to meet our target of completing the capacity expansion for flu vaccines by the end of 2011. We are simultaneously evaluating the construction plan of production facilities for our current pipeline products, such as the EV71 vaccine, at the Changping facility. We are pleased with the progress that is being made at our Dalian joint venture as the formal business license has been obtained. The application to conduct clinical trials for the proprietary mumps vaccine developed by Sinovac Dalian was submitted to the SFDA in April and the production lines are being upgraded. In order to enhance the market competency of our products and to facilitate entry into international market, the production lines at two facilities are being designed and constructed according to the WHO GMP standards."
Mr. Yin continued, "This year the SFDA continues to work closely with the World Health Organization (WHO) to improve manufacturing across China in accordance with GMP standards. In July 2010, Sinovac was selected as one of the five companies at which the WHO experts conducted the training for China's SFDA GMP site inspectors. Although the Chinese vaccine market has been significantly affected by unfounded media reports, we believe that the public appeal to improve the vaccine quality standards represents a significant market opportunity for companies, such as Sinovac, that supply high quality vaccine products."
Mr. Yin concluded, "We appreciate the continued support and understanding of our investors. We are continuing to refine our domestic and international sales strategies, expand our manufacturing capacity, and advance our vaccine development pipeline to build long-term value for our shareholders."
Financial Review for Second Quarter Ended June 30, 2010
Second quarter 2010 results included the consolidation of the financial results from the 30%-owned joint venture, Sinovac Dalian, following its formation in January 2010.
Sales for the second quarter of 2010 were $10.3 million, up 131% from $4.4 million in the first quarter of 2010 and down 49% from $20.0 million for the second quarter of 2009. The second quarter 2010 sales were impacted in part by the continuing weakness in the private pay market following the unfounded media reports about vaccine safety in China's Shanxi province and by vaccine purchases from the Ministry of Health (MOH) that has not recurred. In the second quarter of 2009, the Company sold 2.08 million doses of Healive to MOH as part of the response in connection with a flood relief effort.
Sinovac's sales breakdown by product was as follows. Three months ended June 30 2010 2009 Sales Healive $5,954,172 $18,018,340 Bilive 2,722,710 2,103,573 Anflu (765) (103,586) Panflu.1 (H1N1) 1,587,589 -- Total $10,263,706 $20,018,327
Sales of the Panflu.1 (H1N1) vaccine represented 15.5% of total sales for the three months ended June 30, 2010. The H1N1 vaccine was sold to the Chinese government in accordance with the government purchase program.
Gross profit for the second quarter of 2010 was $8.5 million, with a gross margin of 82.7%, compared to $16.3 million and a gross margin of 81.2% for the same period of 2009. The gross margin for the second quarter of 2010 increased due to the product mix during the current year quarter. After deducting depreciation of land use rights and amortization of licenses and permits from gross profit, the adjusted gross margin was 80.7% and 80.2% for the second quarter of 2010 and 2009, respectively.
Selling, general and administrative expenses for the second quarter of 2010 were $4.1 million, compared to $4.9 million in the same period of 2009. SG&A expenses as a percentage of second quarter 2010 sales were 40%, compared to 24% during the second quarter of the prior year. The higher SG&A expenses as a percentage of revenue resulted from the additional G&A expenses associated with the 30%-owned joint venture, Sinovac Dalian, partly offsetting the lower selling costs associated with the second quarter 2010 revenues.
Net research and development expenses for the second quarter 2010 were $1.5 million, compared to $550,000 in the same period of 2009. The increased R&D expenses in the second quarter of 2010 were primarily related to the continued development of EV71 vaccine, pneumococcal conjugated vaccine, rabies vaccines for human and animals, along with the mumps vaccine, which is currently under development at Sinovac Dalian.
Depreciation of property, plant and equipment and amortization of license and permits for the second quarter of 2010 rose to $507,000, compared to $167,000 for the same period of last year. The increase was primarily attributable to depreciation expense at Sinovac Dalian that was included in the second quarter 2010 consolidated results.
Total operating expenses for the second quarter of 2010 were $6.1 million, compared to $5.6 million in the comparative period in 2009.
The operating income for the three months ended June 30, 2010 was $2.4 million, compared to $10.7 million for the same period of the prior year. The lower operating income in the second quarter of 2010 was attributable to the increased administrative expenses from Sinovac Dalian, reduced sales and higher R&D expenses.
Net income for the second quarter of 2010 included $423,000 of interest and financing expenses, $458,000 of interest and other income and $891,000 of income tax expense. Net income for the same period of 2009 included $199,000 of interest and financing expenses, $73,000 of interest and other income, and $2.2 million of income tax expenses. Net income attributable to shareholders for second quarter of 2010 was $1.0 million, or $0.02 per diluted share, as compared to net income attributable to shareholders of $5.8 million, or $0.14 per diluted share, in the same period of 2009.
As of June 30, 2010, Sinovac's cash and cash equivalents totaled $94.6 million, compared to $75.0 million as of December 31, 2009. The increase in cash and cash equivalents primarily reflected the contribution of approximately $62.0 million in net proceeds from the public offering of common shares, which was closed in February 2010.
Financial Review for Six-Month Period Ended June 30, 2010
Results for the six-month period of 2010 included the consolidation of the financial results from the 30%-owned joint venture, Sinovac Dalian, following its formation in January 2010.
Sales for the six-month period of 2010 were $14.7 million, down 45% from $26.6 million for the same period of 2009. The lower sales in the first half of 2010 were attributable to adverse impact of the unfounded media reports in the Shanxi province on the domestic vaccine market and the absence of government purchases in the current year for disease control in the flood region.
Sinovac's sales breakdown by product was as follows. Six months ended June 30 2010 2009 Sales Healive $8,493,807 $22,920,655 Bilive 3,263,769 3,299,750 Anflu 31,032 364,021 Panflu.1 (H1N1) 2,918,997 -- Total $14,707,605 $26,584,426
Sales of the Panflu.1 (H1N1) vaccine represented 19.8% of total sales for the six months ended June 30, 2010. The H1N1 vaccine was sold to the Chinese government in accordance with the government purchase program.
Gross profit for the six-month period of 2010 was $12.0 million, with a gross margin of 81.9%, compared to $21.4 million and a gross margin of 80.4% for the same period of 2009. The gross margin for the first half of 2010 increased due to the product mix during the current year. After deducting depreciation of land use rights and amortization of licenses and permits from gross profit, adjusted gross margin was 81.2% and 80.0% for the six-month period of 2010 and 2009, respectively.
Selling, general and administrative expenses for the first six months of 2010 were $7.2 million, compared to $8.4 million in the same period of 2009. SG&A expenses as a percentage of six-month period 2010 sales were 49%, compared to 32% for the same period of the prior year. The higher SG&A expenses as a percentage of revenue resulted from the additional G&A expenses associated with the 30%-owned joint venture, partly offsetting the lower selling costs associated with the first half 2010 revenues.
Net research and development expenses for the first six months of 2010 were $2.4 million, compared to $1.3 million in the same period of 2009. The increased R&D expenses in the six-month period of 2010 were primarily related to the continued development of EV71 vaccine, pneumococcal conjugated vaccine, rabies vaccines for human and animals, along with the mumps vaccine, which is currently under development at Sinovac Dalian.
Depreciation of property, plant and equipment and amortization of license and permits for the six-month period of 2010 rose to $932,000, compared to $332,000 for the same period of last year. The increase was primarily attributable to depreciation expense at Sinovac Dalian that was included in the second quarter 2010 consolidated results.
Total operating expenses for the first six months of 2010 were $10.5 million, compared to $10.0 million in the comparative period in 2009.